文献速递骨质疏松与代谢性骨病创伤骨科

维生素K对成人骨密度和骨折的影响:随机对照试验的系统综述与荟萃分析更新

Effect of vitamin K on bone mineral density and fractures in adults: an updated systematic review and meta-analysis of randomised controlled trials.
PubMed 文献 · Osteoporos Int · 2019-05-10

该系统综述与荟萃分析更新纳入36项随机对照试验,评估口服维生素K补充对成人骨密度和骨折的影响。在绝经后或骨质疏松患者中,维生素K可能降低临床骨折风险(OR 0.72,95%CI 0.55至0.95),但对椎体骨折和骨密度无显著影响,证据尚不足以确认临床骨折的获益。

要点

  • 绝经后或骨质疏松患者中,维生素K组临床骨折风险低于对照组(OR 0.72,95%CI 0.55至0.95)。
  • 维生素K对椎体骨折无显著影响(OR 0.96,95%CI 0.83至1.11)。
  • 腰椎骨密度较基线的百分比变化在1年和2年时维生素K组高于对照组,但去除高偏倚风险试验后差异未达统计学显著。

核心结论

  • 对于绝经后或骨质疏松患者,没有证据表明维生素K影响骨密度或椎体骨折;它可能降低临床骨折风险,但证据不足以确认这一点。
  • 对于其他患者群体,试验太少,无法得出结论。

研究设计与样本

  • 系统综述与荟萃分析更新,检索MEDLINE、EMBASE、CENTRAL、CINAHL、clinicaltrials.gov和WHO-ICTRP数据库,纳入评估口服维生素K补充对成人骨密度或骨折影响的随机对照试验,共纳入36项研究。

主要发现

  • 在绝经后或骨质疏松患者中,维生素K组任何临床骨折的比值比低于对照组(OR 0.72,95%CI 0.55至0.95);限制为低偏倚风险试验后,OR为0.76(95%CI 0.58至1.01)。
  • 维生素K组与对照组椎体骨折无差异(OR 0.96,95%CI 0.83至1.11)。
  • 腰椎骨密度较基线的百分比变化,维生素K组在1年时平均差为0.93%(95%CI -0.02至1.89),在2年时为1.63%(95%CI 0.10至3.16),均高于对照组;但去除高偏倚风险试验后差异趋于减小且未达统计学显著。
  • 6个月时,髋部骨密度较基线的百分比变化维生素K组高于对照组(MD 0.42%,95%CI 0.01至0.83),股骨亦高于对照组(MD 0.29%,95%CI 0.17至0.42)。
  • 其他解剖部位的骨密度无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 对于其他患者群体,试验太少,无法得出结论。
  • 证据不足以确认维生素K对临床骨折的获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Vitamin K may affect bone mineral density and fracture incidence. Since publication of a previous systematic review the integrity of some of the previous evidence has been questioned and further trials have been published. Therefore an update to the systematic review was required. INTRODUCTION: This systematic review was designed to assess the effectiveness of oral vitamin K supplementation for increasing bone mineral density and reducing fractures in adults. METHODS: MEDLINE, EMBASE, CENTRAL, CINAHL, clinicaltrials.gov, and WHO-ICTRP were searched for eligible trials. Randomised controlled trials assessing oral vitamin K supplementation that assessed bone mineral density or fractures in adult populations were included. A total of 36 studies were identified. Two independent reviewers extracted data using a piloted extraction form. RESULTS: For post-menopausal or osteoporotic patients, meta-analysis showed that the odds of any clinical fracture were lower for vitamin K compared to controls (OR, 0.72, 95%CI 0.55 to 0.95). Restricting the analysis to low risk of bias trials reduced the OR to 0.76 (95%CI, 0.58 to 1.01). There was no difference in vertebral fractures between the groups (OR 0.96, 95%CI 0.83 to 1.11). In the bone mineral density meta-analysis, percentage change from baseline at the lumbar spine was higher at 1 year (MD 0.93, 95%, CI - 0.02 to 1.89) and 2 years (MD 1.63%, 95%CI 0.10 to 3.16) for vitamin K compared to controls; however, removing trials at high risk of bias tended to result in smaller differences that were not statistically significant. At 6 months, it was higher in the hip (MD 0.42%, 95%CI 0.01 to 0.83) and femur (MD 0.29%, 95%CI 0.17 to 0.42). There was no significant difference at other anatomical sites. CONCLUSIONS: For post-menopausal or osteoporotic patients, there is no evidence that vitamin K affects bone mineral density or vertebral fractures; it may reduce clinical fractures; however, the evidence is insufficient to confirm this. There are too few trials to draw conclusions for other patient groups.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Mott A, Bradley T, Wright K, et al. Effect of vitamin K on bone mineral density and fractures in adults: an updated systematic review and meta-analysis of randomised controlled trials. Osteoporos Int. 2019. PMID: 31076817. doi:10.1007/s00198-019-04949-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。